How to Play NVO Stock After New Drug's Success in Obesity Study
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Managed Healthcare Executive2d
FDA Approves Ozempic to Reduce Kidney Disease in Type 2 Diabetes
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Medscape6d
A Guide for Discussing GLP-1s as Obesity Treatments
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
pharmaphorum5d
The Ozempic dilemma: Balancing demand, supply, and patient safety in a viral GLP-1 world
Only three drugs – Novo Nordisk’s Wegovy and Saxenda ... reported seizing 369 potentially fake Ozempic pens between January and October in 2023, marking the first identification of such ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Sky3d
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Hosted on MSN1d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
pharmaphorum3d
Novo Nordisk’s diabetes treatments approved in EU
The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... company’s latest prefilled insulin pen, FlexTouch, which has an easy auto-injector mechanism.